10-year evolution of day-case hip and knee arthroplasty: a Danish nationwide register study of 166,833 procedures from 2010 to 2020

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 1.02 MB, PDF document

Background and purpose — No previous studies have investigated the use of day-case arthroplasty in Denmark on a national scale. We investigated the frequency of day-case surgery in total hip (THA), total knee (TKA), and unicompartmental knee arthroplasty (UKA) from 2010 to 2020 in Denmark. Patients and methods — Primary unilateral THAs, TKAs, and UKAs performed for osteoarthritis were identified in the Danish National Patient Register using procedural and diagnosis codes. Day-case surgery was defined as discharge on the day of surgery. 90-day readmissions were defined as any overnight admissions following discharge. Results — From 2010 to 2020 Danish surgical centers performed 86,070 THAs, 70,323 TKAs, and 10,440 UKAs. From 2010 to 2014, less than 0.5% of THAs and TKAs were day-case procedures. They increased to 5.4% (95% confidence interval [CI] 4.9–5.8) of THAs and 2.8% (CI 2.4–3.2) of TKAs in 2019. From 2010 to 2014, 11% of UKAs were day-case procedures, but they increased to 20% (CI 18–22) in 2019. This increase was driven by a few surgical centers (3–7 centers). In 2010, readmission rates within 90 days of surgery were 10% after THAs and 11% after TKAs, and 9.4% for both THAs and TKAs in 2019. Readmission rates after UKA fluctuated between 4% and 7%. Conclusion — From 2010 to 2020 the use of day-case surgery in THA, TKA, and UKA increased in Denmark, driven by only a few centers. During the same period read-missions did not increase.

Original languageEnglish
JournalActa Orthopaedica
Volume94
Pages (from-to)178-184
Number of pages7
ISSN1745-3674
DOIs
Publication statusPublished - 2023

Bibliographical note

Funding Information:
The Knowledge Center on Data Protection Compliance in the Capital Region of Denmark approved this study (approval nr. P-2021-132). As this was an observational study with no clinical intervention and using only register data, no approval from regional or national research ethical committees was required and informed consent was waived. No funding was received directly for this study. CBJ has received ph.d. funding from a grant from the Novo Nordisk Foundation unrelated to this study. KG and AT has received research support and speaker fees from Zimmer Biomet, and AT has received research support from Pfizer. NBF has received speaker fees from Masimo Cooperation and Edwards Lifesciences. All of the above conflicts are unrelated to this study.Completed disclosure forms

Publisher Copyright:
© 2023 The Author(s). Published by Medical Journals Sweden,.

ID: 367193933